We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+12.89%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.25B
AUM Growth
+$226M
Cap. Flow
+$21M
Cap. Flow %
0.93%
Top 10 Hldgs %
73.64%
Holding
48
New
2
Increased
21
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$23.9M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$22.5M
3
ABMD
Abiomed Inc
ABMD
+$17.9M
4
INSM icon
Insmed
INSM
+$1.91M
5
UTHR icon
United Therapeutics
UTHR
+$1.8M

Top Sells

Rank Stock Value
1
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$27.4M
2
ALGN icon
Align Technology
ALGN
+$15M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$10.2M
4
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$4.95M
5
QLTI
QLT Inc
QLTI
+$1.24M

Sector Composition

Rank Sector Weight
1 Healthcare 69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$23.1B
$250M 11.14%
1,439,928
+10,000
+0.7% +$1.8M
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$240M 10.68%
3,103,027
-156,018
-5% -$10.2M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$12.4B
$227M 10.1%
1,660,092
+10,300
+0.6% +$1.28M
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$211M 9.38%
2,401,117
+279,260
+13% +$23.9M
ABMD
5
DELISTED
Abiomed Inc
ABMD
$180M 8.01%
2,742,305
+268,681
+11% +$17.9M
AMAG
6
DELISTED
AMAG Pharmaceuticals
AMAG
$151M 6.73%
2,192,141
+5,100
+0.2% +$321K
INSM icon
7
Insmed
INSM
$28.6B
$116M 5.14%
4,733,601
+84,153
+2% +$1.91M
THOR
8
DELISTED
THORATEC CORPORATION
THOR
$114M 5.07%
2,560,303
+22,100
+0.9% +$968K
KYTH
9
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$97.2M 4.32%
1,290,292
-92,430
-7% -$4.95M
ENDP
10
DELISTED
Endo International plc
ENDP
$68.9M 3.06%
864,604
+4,400
+0.5% +$380K
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
$54M 2.4%
2,056,251
+7,000
+0.3% +$185K
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$302M
$49.5M 2.2%
3,897,408
+94,000
+2% +$1.01M
KPTI icon
13
Karyopharm Therapeutics
KPTI
$48M
$47.1M 2.09%
115,435
+52,033
+82% +$22.5M
PRTA icon
14
Prothena Corp
PRTA
$450M
$36.7M 1.63%
695,918
– –
GILD icon
15
Gilead Sciences
GILD
$165B
$35.1M 1.56%
299,500
+8,500
+3% +$929K
MNTA
16
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$33.2M 1.48%
1,455,176
– –
SQNM
17
DELISTED
SEQUENOM INC NEW
SQNM
$30.5M 1.35%
10,023,842
+46,200
+0.5% +$174K
CELG
18
DELISTED
Celgene Corp
CELG
$30.3M 1.35%
262,200
+12,800
+5% +$1.46M
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
$27.9M 1.24%
1,974,376
+18,000
+0.9% +$216K
STAA icon
20
STAAR Surgical
STAA
$1.21B
$25.5M 1.14%
2,642,922
– –
CYBX
21
DELISTED
CYBERONICS INC
CYBX
$24.5M 1.09%
412,000
– –
SHPG
22
DELISTED
Shire pic
SHPG
$23.7M 1.06%
98,300
+3,300
+3% +$818K
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
$20.6M 0.92%
360,600
+17,200
+5% +$1.06M
ARIA
24
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$18.5M 0.82%
2,231,717
– –
HTWR
25
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$17.7M 0.79%
243,868
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q2 2015 Portfolio in Review

As of Q2 2015, Palo Alto Investors held 48 positions worth $2.25B, up 11% from $2.02B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors's Q2 2015 filing shows 2 new, 21 increased, 4 reduced and 3 closed positions. Its largest new stake was Dicerna Pharmaceuticals, Inc.: 70,706 shares worth $986K. The largest sale was Eiger BioPharmaceuticals, Inc., an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 71% a quarter earlier.

  • Palo Alto Investors's largest Q2 2015 buy was Dicerna Pharmaceuticals, Inc.: 70,706 shares worth $986K.
  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q2 2015, an estimated $23.9M increase.
  • Palo Alto Investors's biggest Q2 2015 reduction was Align Technology, cutting an estimated $15M.
  • Palo Alto Investors fully exited Eiger BioPharmaceuticals, Inc. in Q2 2015, selling an estimated $27.4M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $2.25B portfolio in Q2 2015.
  • Palo Alto Investors opened 2 new positions and closed 3 in Q2 2015.
  • Palo Alto Investors's portfolio value rose 11% quarter-over-quarter to $2.25B.

Based on Palo Alto Investors's 13F filing for Q2 2015, filed 14 Aug 2015.